Aurobindo Pharma has rolled out its brand of Molnupiravir- Molnaflu in India for adult COVID patients today. It is available pan-India across all major metros and towns, according to a company statement.
The statement mentioned that earlier last year, Aurobindo had signed a bi-lateral non-exclusive voluntary licensing agreement with Merck Sharpe Dohme, Singapore (MSD), a subsidiary of Merck & Co (US) to manufacture and supply Molnupiravir to over 100 low and middle-income countries (LMICs), including India.
For the licensed version of Molnupiravir, Aurobindo has backward integration with in-house API manufacturing which equips it with stronger control on the quality systems and supply chain. The product will be manufactured at the company’s manufacturing facilities in India that are approved by global regulatory agencies including the US FDA and the UK MHRA. The company has adequate capacities to meet the global demand across the 100+ LMI countries for the product, the statement concluded.